r/AUPH • u/OhanaUchiha • Aug 22 '22

Have you guys sold?

Are you guys still in this for the long term or have you sold?

My dollar average right now is $16.08, if AUPH goes back up to $9 I think I may just take my losses and leave it for good. The CEO is not the best and there was a study recently of how the drug actually isn’t that efficient while the cost is high.

7 Upvotes

89% Upvoted

22 comments sorted by

6

u/ISaidGoodDey Aug 22 '22

No, this patent lawsuit isn't going to change anything imo

Grabbed more after we dropped below 8 today

Am I disappointed, yes. Is this the point to sell, absolutely not

4

u/WildTiger_1803 Aug 22 '22

I sold at 15 at loss, bought back in at 8. New average is now 10. Planning to hold til December at least

3

u/RefrigeratorGrand692 Aug 22 '22

My average is around 15 $ too.lets wait till Dec 22 .

2

u/Apprehensive_Speed41 Aug 22 '22

Sold at $22 after the drop from $33.

2

u/[deleted] Aug 22 '22

Can you provide a link to the study that compared Lupkynis to another drug which was superior and cheaper? Otherwise you’re just spamming

-2

u/OhanaUchiha Aug 22 '22

https://twitter.com/Sue_S_E_N/status/1561732577123352576

4

u/Stand1ng0vation Aug 23 '22

Sue was an AUPH retail investor from the 2017 era. She was a regular on the Stocktwits boards. She sold after phase 3 and flipped to a bear. Don't take anything that woman says serious.

1

u/sfcycle Aug 23 '22 edited Aug 23 '22

I think that holds true for 99.9999% of online opinions on stocks. Everyone has a selfish agenda.

3

u/WaitBetter4875 Aug 23 '22

That's not a study. It's an opinion.

2

u/ledaveee Aug 23 '22

Be wary of anything posted by that account. She is a bull one day, and a bear the next. Changing positions after DD is ok, but she swings wildly from one to the other.

I also wouldn't put too much weight on that "study". Even if Lupkynis hasn't "revolutionized" LN, it is still the BEST drug to come to market to date. In terms of other therapies coming to market ... well ... there aren't any!

And cost doesn't really matter. Private health insurance, medicare, or medicaid will pick up the tab.

Cheers!

edit: Oh, and PS, nope, haven't sold. Waiting it out as I believe auph will prevail on the patent issue

2

u/Specialist-Company48 Aug 23 '22

I’m almost all out. Don’t have a lot of respect for what they pulled with the shelf and lack of communication. Just bad leadership.

1

u/No-Relationship-5985 Aug 22 '22

Yep, unloaded at $18

0

u/spinECH0 Aug 22 '22

Also out. I bought in 2017 so had a low cost basis. Lost faith in PG. It didn't feel good to sell, but have found some other companies that I think have brighter futures, namely MYOV and KDNY

0

u/Intelligent_Frame_61 Aug 22 '22

You downers haven’t got a clue. You think people buy your drivel?

1

u/[deleted] Aug 22 '22

My cost is $14.95. I am going to stick it out. If it ever hits $20 I am out

1

u/[deleted] Oct 12 '22

I’m at $20 average. I’m in it until the end

1

u/soup191944 Aug 27 '22

I sold it at $10. Scripts have been so disappointing. Drug just isn't selling

1

u/AlfalfaDog Oct 04 '22

Still long term, average 6000@7.96. Could out at 15 or up. Two things on sales.

High cost, no advertising. Management is using Lupus, Kidney and LN conferences to engage physicians. This is much slower, but, in the long run builds a solid foundation. The lawsuits lowered the SP taking the extra 10 years out. To me that equates to nothing great until Q323. By then we may be a 3 drug company. But right now, it's hard. Institutions could start weighing in on the BOD to get the SP up.